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RegulationLiver X receptors (LXRs) belong to the nuclear hormone receptor superfamily. Multidrug resistance-associated
protein 2 (MRP2), multidrug resistance 1 (MDR1) and breast cancer resistance protein (BCRP) play an
important role in the efﬂux of a broad range of endogenous and xenobiotic compounds fromhepatocytes. Since
the effects of LXR activation on there transporters have been obscure, we investigated the effects of LXR
agonists, TO901317 and 25-hydroxycholesterol, on MRP2, MDR1, BCRP expression in HepG2 cells and the rat
liver. In an in vitro study, TO901317 increased ABCA1, an LXR target gene, andMRP2mRNA and protein levels.
On the other hand, TO901317 had little effect on MDR1 and BCRP mRNA levels. In an in vivo study, Abca1 and
Mrp2 mRNA and protein levels were increased by TO901317, but TO901317 had no effect on Mdr1a and Bcrp
mRNA levels in the rat liver. Moreover, TO901317-induced MRP2 mRNA expression was blocked by LXRα
knockdown. In this study, we demonstrated that LXR activation induced expression of MRP2 but not that of
MDR1 and BCRP in hepatocytes. The results suggest that agonists for LXR activate transcription of the MRP2
gene in order to promote excretion of endogenous and xenobiotic compounds from hepatocytes into bile.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Multidrug resistance-associated protein 2 (MRP2, ABCC2), multi-
drug resistance 1 (MDR1, ABCB1) and breast cancer resistance protein
(BCRP, ABCG2) belong to the ATP-binding cassette (ABC) superfamily
of transporters. These transporters are localized to the apical
membrane of hepatocytes and mediate efﬂux of a broad range of
endogenous and xenobiotic compounds. MRP2 is responsible for the
transport of a wide variety of organic anions such as bilirubin glucu-
ronide and glutathione conjugates [1]. MDR1 plays a critical role in
drug absorption, biliary excretion, renal secretion and central nervous
system (CNS) entry of a broad range of hydrophobic substrates [2,3].
BCRP has been implicated in multidrug resistance during chemother-
apy, secretion of drugs into breast milk [4] and limitation of the oral
bioavailability of sulfasalazine [5]. It has been reported that these
transporters are regulated by various nuclear receptors. MRP2 has
been shown to be regulated by pregnane X receptor (PXR), farnesoid X
receptor (FXR) and constitutive androstane receptor (CAR). Increased
MRP2 mRNA expression and transactivation has been found following
treatmentwith agonists for PXR, FXR andby the CAR activator [6].MDR1
hasbeen shown tobe regulatedbyPXRandCAR [7–9] andBCRPhasbeen
shown to be regulated by peroxisome proliferator-activated receptor
gamma (PPARγ) in human dendritic cells [10]. The liver X receptors
(LXRα and LXRβ) are transcription factors that belong to the nuclear).
ll rights reserved.hormone receptor superfamily. LXRs form heterodimers with the
retinoid X receptor (RXR) to bind to speciﬁc response elements in
promoters or enhancers of the target gene. The LXRβ isoform is ubi-
quitously expressed in adults, whereas the expression of LXRα is pre-
dominantly restricted to tissues such as the liver, adipose tissue, kidney
and small intestine. The formation of HDL by disposal of excess choles-
terol and phospholipid from peripheral tissues and the liver is mediated
by LXRα, which increases expression of genes encoding ATP-binding
cassette proteins, ABCA1 and ABCG1 [11–14], bile acid metabolic
enzymes [15] and apolipoproteins [16]. However, the effects of LXR
activation on MRP2, MDR1 and BCRP expression have been obscure.
The aim of this study was to determine the effects of LXR agonists
on MRP2, MDR1 and BCRP expression in HepG2 cells and the rat liver.
2. Materials and methods
2.1. Cell culture
HepG2 cells were kept in Dulbecco's modiﬁed Eagle's medium
(Sigma Aldrich, Tokyo, Japan) with 10% fetal bovine serum (ICN
Biomedicals, Inc., Aurora, OH) and 1% penicillin–streptomycin at 37 °C
under 5% CO2 as described previously [17].
2.2. Animals
Male Wistar rats, aged 7 to 8 weeks (260–305 g in weight), were
obtained from Jla (Tokyo, Japan). The housing conditions were des-
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and approved by the Hokkaido University Animal Care Committee in
accordance with the “Guide for the Care and Use of Laboratory
Animals”. The dosage of TO901317 suspended with methylcellulose
was 10 mg/kg for rats. Rats were starved for 6 or 12 h after admi-
nistration and euthanized.
2.3. Immunocytochemistry
HepG2 cells were washed once with PBS and ﬁxed with methanol
for 5 min. After the ﬁxed cells had been washed three times with PBS,
10% FBS was added and the cells were incubated for 1 h at room
temperature. The cells were then reacted with LXRα (P-20) (Santa
Cruz Biotechnology, Santa Cruz, CA) (diluted 1:100) for 24 h at room
temperature. Then the cells were washed three times with PBS and
treated with donkey anti-goat IgG-FITC secondary antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) at a dilution of 1:400. Nuclei were
stained with DAPI. The samples were then visualized by using a
confocal microscope (Zeiss LSM-510; Carl Zeiss Inc., Thornwood, NY).
2.4. Nuclear extraction
Nuclear extractionwas carried out as described in a previous report
with some modiﬁcation [19]. HepG2 cells were seeded on 6-well
plastic plates. Following cell attachment (24 h), 1 or 10 μM TO901317
was added for 24h. Total protein extractswere prepared from the cells.
The cellswere scraped and centrifuged at 1300×g for 1min at 4 °C. The
pellet was suspended in 1 mL of PBS and centrifuged at 1300×g for
1 min at 4 °C. The resulting pellet was suspended in 100 μL solution 1
containing 0.6% Nonidet® P-40, 150mMNaCl, 10mMHEPES (pH 7.9),
1 mM EDTA and 0.5 mM PMSF. The suspension was allowed to stand
for 5 min on ice and centrifuged at 2100×g for 5 min at 4 °C, and the
pellet was suspended in 50 μL solution 2 containing 25% glycerol,
20 mM HEPES (pH 7.9), 420 mM NaCl, 1.2 mM MgCl2, 0.2 mM EDTA,
0.5 mM dithiothreitol, 0.5 mM PMSF, 2 mM benzamidine, 5 μg/mL
pepstatin and leupeptin. The suspension was sonicated for 20 min at
4 °C and centrifuged at 3000×g for 15 s at room temperature. The
protein concentration in the clear supernatant was determined by the
method of Lowry et al. [20].
2.5. Western blot analysis
Western blot analysis was performed as described previously [21].
HepG2 cells were seeded on 6-well plastic plates. Following cell
attachment (24 h), various concentrations of reagents were added for
24 h. Total protein extracts were prepared from the cells. The cells
were scraped and centrifuged at 1300×g for 1 min at 4 °C. The pellet
was suspended in 1 mL of PBS and centrifuged at 1300×g for 1 min at
4 °C. The resulting pellet was suspended in 100 μL lysis buffer
containing 1% Triton X-100, 0.1% SDS and 4.5 M urea. The suspension
was allowed to stand for 5 min on ice and was sonicated for 15 min at
4 °C. The suspension was then centrifuged at 12 000×g for 15 min at
4 °C. The liver crude membrane was used for Western blot analysis.
The sample was prepared as described previously [22]. The protein
concentration in the clear supernatant was determined by themethod
of Lowry et al. [20]. The samples were denatured at 100 °C for 3 min in
a loading buffer containing 0.1 M Tris–HCl, 4% SDS, 10% 2-mercap-
toethanol, 20% glycerol, 0.004% BPB and 9 M urea and separated on
4.5% stacking and 10% SDS polyacrylamide gels. Proteins were trans-
ferred electrophoretically onto nitrocellulose membranes at 15 V for
90 min. The membranes were blocked with PBS containing 0.05%
Tween 20 (PBS/T) and 10% non-fat dry milk for 1 h at room
temperature. After being washed with PBS/T, the membranes were
incubated with mouse anti-Nucleoporin p62 monoclonal antibody
(BD Biosciences, Wobarn, MA) (diluted 1:1000), Insulin Rβ (C-19)
(Santa Cruz Biotechnology, Santa Cruz, CA) (diluted 1:200), LXRα(P-20) (Santa Cruz Biotechnology, Santa Cruz, CA) (diluted 1:200),
mouse monoclonal antibody to MRP2 (Abcam, Cambridge, UK)
(diluted 1:50) or mouse anti-actin monoclonal antibody (Chemicon,
Temecula, CA) (diluted 1:500) for 24 h at room temperature and
washed three times with PBS/T for 10 min each time. The membranes
were subsequently incubated for 1 h at room temperature with
horseradish peroxidase-conjugated goat anti-mouse secondary anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA), horseradish
peroxidase-conjugated goat anti-rabbit secondary antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) and horseradish peroxidase-
conjugated donkey anti-goat secondary antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA) at a dilution of 1:2000 or 4000 and washed
three timeswith PBS/T for 10mineach time. Thebandswere visualized
by enhanced chemiluminescence according to the instructions of the
manufacturer (Amersham Biosciences Corp., Piscataway, NJ).
2.6. Quantitative real-time PCR
Quantitative real-time PCR was performed using an ABI PRISM
7700 Sequence Detector (Applied Biosystems, Foster City, CA) with
Platinum® SYBR® Green qPCR SuperMix UDG (Invitrogen, Carlsbad,
CA) following the manufacturer's protocol as described previously
[23]. PCR was performed using human ABCA1-speciﬁc primers
through 40 cycles of 94 °C for 15 s, 56 °C for 30 s and 72 °C for 30 s;
using human MRP2-speciﬁc primers through 40 cycles of 94 °C for
15 s, 60 °C for 30 s and 72 °C for 30 s; using human MDR1-speciﬁc
primers through 40 cycles of 94 °C for 15 s, 58 °C for 30 s and 72 °C for
30 s; using human BCRP-speciﬁc primers through 40 cycles of 94 °C
for 15 s, 58 °C for 30 s and 72 °C for 30 s; using human LXRα-speciﬁc
primers through 40 cycles of 94 °C for 15 s, 55 °C for 30 s and 72 °C for
30 s; or using human GAPDH-speciﬁc primers after pre-incubation at
95 °C for 15 min. The primers speciﬁc to hABCA1, hMRP2, hMDR1,
hBCRP, hLXRα and hGAPDH were designed on the basis of sequences
in the GenBank™ database (accession no.: AF285167, NM_000392,
NM_000927, NM_004827, NM_005693 and NM_002046, respective-
ly). The sequences of the speciﬁc primers were as follows: the sense
sequence was 5′-AAC AGT TTG TGG CCC TTT TG-3′ and the antisense
sequence was 5′-AGT TCC AGG CTG GGG TAC TT-3′ for hABCA1; the
sense sequence was 5′-ACA GAG GCT GGT GGC AAC C-3′ and the
antisense sequence was 5′-ACC ATT ACC TTG TCA CTG TCC ATG A-3′
for hMRP2; the sense sequence was 5′-TGC TCA GAC AGG ATG TGA
GTT G-3′ and the antisense sequence was 5′-AAT TAC AGC AAG CCT
GGA ACC-3′ for hMDR1; the sense sequence was 5′-TTA TCC GTG GTG
TGT CTG GA-3′ and the antisense sequence was 5′-TTC CTG AGG CCA
ATA AGG TG-3′ for hBCRP; the sense sequence was 5′-TTC ATC AAC
CCC ATC TTC-3′ and the antisense sequence was 5′-ACC AGT TTC ATT
AGC ATC C-3′ for hLXRα; and the sense sequencewas 5′-AAG GTC ATC
CCT GAG CTG AA-3′ and the antisense sequence was 5′-TTC TAG ACG
GCA GGT CAG GT-3′ for hGAPDH. PCRwas performed using rat Abca1-
speciﬁc primers through 40 cycles of 94 °C for 15 s, 61 °C for 30 s and
72 °C for 30 s; using rat Mrp2-speciﬁc primers through 40 cycles of
94 °C for 15 s, 52 °C for 30 s and 72 °C for 30 s; using ratMdr1a-speciﬁc
primers through 40 cycles of 94 °C for 15 s, 50 °C for 30 s and 72 °C for
30 s; using rat Bcrp-speciﬁc primers through 40 cycles of 94 °C for
15 s, 50 °C for 30 s and 72 °C for 30 s; or using rat Gapdh-speciﬁc
primers after pre-incubation at 95 °C for 15 min. The primers speciﬁc
to rAbca1, rMrp2, rMdr1a, rBcrp and rGapdh were designed on the
basis of sequences in the GenBank™ database (accession no.:
NM_178095, NM_012833, NM_133401, AB094089 and AF106860,
respectively). The sequences of the speciﬁc primers were as follows:
the sense sequence was 5′-CAG GCT GAT GTC AGT CTC CA-3′ and the
antisense sequence was 5′-GGC TTC AGG ATG TCC ATG TT-3′ for
rAbca1; the sense sequencewas 5′-TGA TCG GTT TCG TGA AGAGCT-3′
and the antisense sequence was 5′-ACG CAC ATT CCC AAC ACA AA-3′
for rMrp2; the sense sequence was 5′-GCA GGT TGG CTG GAC AGA TT-
3′ and the antisense sequence was 5′-GGA GCG CAA TTC CAT GGA TA-
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CA-3′ and the antisense sequence was 5′-TGA GTT TCC CAG AAG CCA
GT-3′ for rBcrp; and the sense sequence was 5′-ATG GGA AGC TGG
TCA TCA AC-3′ and the antisense sequence was 5′-GTG GTT CAC ACC
CAT CAC AA-3′ for rGapdh. The PCR products were normalized to
ampliﬁed GAPDH, which was the internal reference gene (house-
keeping gene). Standard curves were prepared for each target and
housekeeping gene. A standard curve was established between the
threshold cycles (Ct) and the log10 (copy numbers) by using Applied
Biosystems sequence detection system software, version 1.9.1. The
software calculates the relative amount of the target gene and the
housekeeping gene based on the Ct.
2.7. LXRα small interfering RNA (siRNA) and siRNA transfection
Two kinds of Silencer® Validated siRNA (ID nos. 5370 and 5458)
targeted to different regions of the LXRα gene and nontargeting siRNA
as a Silencer® Negative control no. 1 siRNA were purchased from
Ambion (Austin, TX). Delivery of siRNAs into HepG2 cells was
performed by reverse transfection methods as per the manufacturer's
protocol. Six microliters of nontargeting siRNA or LXRα siRNA (2 μM)
and 194 μL of OPTI-MEM® I Reduced Serum Medium (GIBCO, Grand
Island, NY) were mixed in 12-well plastic plates and incubated at
room temperature for 10 min after addition of 2 μL of Lipofectamine™
RNAiMAX (Invitrogen, Carlsbad, CA). Then 1 mL of suspended HepG2
cells (1.0×105 cells/mL) in growth medium without antibiotics was
added. Following siRNA transfection (24 h), themediumwas replaced
with fresh normal growth medium and then the cells were used for
analysis and experimentation at the times indicated.
2.8. MTT assay
The 3-(4,5-dimethyl-thiazole-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT) assay was performed as described previously [24] with a
certain modiﬁcation. MTT is normally reduced by dehydrogenases of
viable cells and transformed to formazan. The assay detects living,
but not dead, cells and the signal generated is dependent on the
degree of activation of the cells. For the MTT assay, HepG2 cells were
seeded on 96-well plastic plates and various concentrations of non-Fig. 1.Nuclear translocation of LXRα induced by TO901317 in HepG2 cells (A), existence of nu
nuclear extract of HepG2 cells (B). (A) HepG2 cells were treated with TO901317 (1 and 1
(green). Nuclei were stained with DAPI (blue). Scale bar shows 10 μm. Data shown are typica
method of Deryckere et al. [19]. HepG2 cells were treated with TO901317 (1 and 10 μM) fotargeting siRNA or LXRα siRNA were added for the times indicated.
At 1 h before the end of treatment, 10 μL of PBS containing MTT
solution (0.5%) was added, and the cells were incubated for a fur-
ther 1 h. The MTT medium was then replaced with 0.2 ml
dimethylsulfoxide, and absorbance was read at 590 nm. Absorbance
measured in MTT assays was expressed as percent of the control
(deﬁned as 100%).
2.9. Statistical analyses
Student's t-test was used to determine the signiﬁcance of diffe-
rences between two group means. Statistical signiﬁcance among
means of more than two groups was determined by one-way ana-
lysis of variance (ANOVA). Statistical signiﬁcance was deﬁned as
pb0.05.
3. Results
3.1. Effect of LXR activation on expression of ABC transporters in HepG2
cells
First, we conﬁrmed that whether TO901317, a nonsteroidal syn-
thetic LXR agonist, activates LXR. TO901317 (1, 10 μM) promoted
LXRα translocation from the cytosol to nuclei (Fig. 1A). Moreover,
nucleoporin, localized to the nuclei, existed in greater abundance in
the nuclear extract than in the cytosol, and insulin Rβ, localized to the
plasma membrane, existed in the cytosol fraction (Fig. 1Ba and b). In
addition, TO901317 increased LXRα protein level in the nuclear
extract (Fig. 1Bc). These results suggest that TO901317 activated
LXRα in HepG2 cells. Next, to clarify the effect of LXRα activation on
ABC transporters, we examined changes in the mRNA levels of ABCA1,
which is an LXR target gene, MRP2, MDR1 and BCRP induced by
TO901317 in HepG2 cells. TO901317 up-regulated ABCA1 and MRP2
mRNA levels in a concentration-dependent manner (Fig. 2A and B).
On the other hand, TO901317 had little effect on MDR1 and BCRP
mRNA levels (Fig. 2C and D). These results suggest that MRP2 mRNA
expression, but not that of MDR1 and BCRP, is regulated via an LXR-
dependent pathway. Next, we examined time courses of the effects of
TO901317 on ABCA1 and MRP2 mRNA levels in HepG2 cells. ABCA1cleoporin (a) and insulin Rβ (b) and effect of TO901317 on LXRα protein level (c) in the
0 μM) for 24 h. Localization of LXRα was determined using an antibody against LXRα
l results of three independent experiments. (B) Nuclei and cytosol were separated by the
r 24 h. Data shown are typical results of three independent experiments.
Fig. 2. Effects of TO901317 on ABCA1 (A), MRP2 (B), MDR1 (C) and BCRP (D) mRNA levels in HepG2 cells. HepG2 cells were treated with TO901317 (0.1–10 μM) for 24 h. Each
column represents the mean with SD of 6 determinations. ⁎⁎Signiﬁcantly different from control at pb 0.01.
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(Fig. 3A). Moreover, we investigatedwhetherMRP2mRNA expression
induced by TO901317 correlated with the protein expression in
HepG2 cells. As shown in Fig. 3B, TO901317 increased ABCA1 and
MRP2 protein levels in a concentration-dependent manner. Naturally
occurring oxysterols, mainly derivatives of cholesterol, function as
agonists for LXR. 25-Hydroxycholesterol (25-OHC), one of theFig. 3. Time courses of TO901317 effects on ABCA1 (a) and MRP2 (b) mRNA levels (A) and
HepG2 cells were treated with TO901317 (1 μM) for 1–72 h. Each point represents the mean
cells were treated with TO901317 (0.1–10 μM) for 24 h. Data shown are typical results of toxysterols, also increased ABCA1 and MRP2 mRNA and protein levels
and protein (Fig. 4A and B).
3.2. In vivo effects of LXR activation on mRNA levels of ABC transporters
To conﬁrm the abovementioned ﬁndings in vivo, TO901317 was
given to rats at 10 mg/kg as described previously with a certaineffects of TO901317 on ABCA1 (a) and MRP2 (b) protein levels (B) in HepG2 cells. (A)
±SD of 5–6 determinations. ⁎Signiﬁcantly different from control at pb 0.05. (B) HepG2
hree independent experiments.
Fig. 4. Effects of 25-hydroxycholesterol (25-OHC) on ABCA1 (a) and MRP2 (b) mRNA levels (A) and protein levels (B) in HepG2 cells. (A) HepG2 cells were treated with 25-
hydroxycholesterol (25–75 μM) for 24 h. Each column represents the mean with SD of 3–8 determinations. ⁎Signiﬁcantly different from control at pb 0.05. (B) HepG2 cells were
treated with 25-hydroxycholesterol (25–75 μM) for 24 h. Data shown are typical results of three independent experiments.
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increased in the rat liver at both 6 and 12 h after oral administration of
10 mg/kg TO901317 (Fig. 5Aa and b). On the other hand, TO901317
had no effect on Mdr1a and Bcrp mRNA levels (Fig. 5Ac and d).Fig. 5. Effects of TO901317 on Abca1 (a), Mrp2 (b), Mdr1a (c) and Bcrp (d) mRNA levels (A)
administered the methylcellulose with or without 10 mg/kg TO901317 for 6 or 12 h. Each co
control at pb 0.05. (B) Male Wistar rats were administered the methylcellulose with or
independent experiments.Moreover, TO901317 up-regulated Abca1 and Mrp2 protein levels at
both 6 and 12 h after oral administration of 10 mg/kg TO901317 (Fig.
5B). These results were completely in agreement with the results of
the in vitro study (Fig. 2).and Abca1 (a) and Mrp2 (b) protein levels (B) in the rat liver. (A) Male Wistar rats were
lumn represents the mean with SD of 3–4 determinations. ⁎Signiﬁcantly different from
without 10 mg/kg TO901317 for 6 or 12 h. Data shown are typical results of three
Fig. 6. siRNA-mediated silencing of LXRα mRNA level in HepG2 cells (A) and effect of LXRα siRNA on viability of HepG2 cells (B). (A) HepG2 cells were transfected with negative
control or LXRα siRNAs (1 and 10 nM) for 72 h. Each column represents the mean with SD of 3 determinations. ⁎Signiﬁcantly different from negative control at pb 0.05. (B) Cell
viability was measured by the MTT assay. HepG2 cells were transfected with negative control or LXRα siRNAs (1 and 10 nM) for 72 h. Each column represents the mean with SD of 6
determinations.
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To clarify whether regulation of MRP2 expression is associated
with an LXRα-dependent pathway, we examined the effect of LXRα
knockdown on TO901317-induced MRP2 expression. First, quantita-
tive real-time RT-PCR was performed to quantify LXRα mRNA levels
at 72 h after transfection of HepG2 cells with siRNA. In this study,
different siRNA constructs targeted to the LXRα gene, LXRα siRNA
nos. 5370 and 5458, were used. The negative control siRNA did not
affect LXRαmRNA level at 72 h after transfection compared with that
in cells not transfected with siRNA (data not shown). Therefore, we
used this negative control siRNA as a control in this study. Two
siRNAs, nos. 5370 and 5458 (1 and 10 nM), for LXRα signiﬁcantly
decreased LXRα mRNA level in HepG2 cells at 72 h after transfection
(Fig. 6A). The effect of 10 nM siRNAs was stronger than that of 1 nM
siRNAs. On the other hand, these LXRα siRNAs (1 and 10 nM) had
little effect on viability of HepG2 cells (Fig. 6B). Thus, we selected
subsequently used LXRα siRNA at a concentration of 10 nM.
TO901317-induced MRP2 mRNA alteration (Fig. 7A) was blocked
by LXRα siRNAs nos. 5370 and 5458 transfected to HepG2 cells (Fig.
7B and C). These results suggest that MRP2 expression is regulated by
an LXRα-dependent pathway.Fig. 7. Effect of LXRα siRNA on TO901317-inducedMRP2mRNA level in HepG2 cells. HepG2 c
with TO901317 (1 and 10 μM) for 24 h. Each column represents the mean with SD of 3–
signiﬁcant.4. Discussion
In this study, we showed that LXR activation induced expression of
the ABC transporter MRP2 in HepG2 cells and the rat liver. This is ﬁrst
study to examine the effect of LXR activation on the expression of
MRP2.
LXR are members of the nuclear hormone receptor superfamily
represented by two subtypes, LXRα and LXRβ [26–28]. Oxysterols
have been identiﬁed as endogenous agonists, and TO901317 is known
to be a nonsteroidal synthetic agonist for both subtypes [29–30]. These
receptors play signiﬁcant roles in cholesterol homeostasis [31]. LXR
forms a heterodimer with the RXR to promote transcription activity of
target genes. The genes encode several important proteins including
ABCA1 that facilitate cholesterol removal from the liver and macro-
phages are targets of LXR. We used ABCA1 expression alteration as a
positive control of LXR activation in this study. MRP2, which is a
member of the ABC superfamily of transporters, consists of two
ATP-binding domains and 12 membrane-spanning regions. MRP2 is a
190-kDa phosphoglycoprotein localized in the apical membrane of
hepatocytes and is involved in the transport of a wide variety of
organic anions such as bilirubin glucuronide and glutathione con-
jugates. The transport of organic anions via MRP2 is a major drivingells were transfected with negative control or LXRα siRNAs (10 nM) for 72 h and treated
6 determinations. ⁎Signiﬁcantly different from control at pb 0.05, ⁎⁎pb 0.01. N.S., not
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the transport of xenobiotics, including the anti-cancer drugs cisplatin,
anthracyclines, Vinca alkaloids and methotrexate [32–37]. MRP2 has
been shown to be regulated by the nuclear receptors PXR, FXR and
CAR. Increased MRP2 expression has been noted following treat-
ment with agonists for PXR (rifampicin, hyperforin), agonists for FXR
(chenodeoxycholic acid, GW4064) and a CAR activator (phenobar-
bital) [6]. However, the involvement of LXR in MRP2 regulation is
unknown. TO901317, a nonsteroidal synthetic LXR agonist, up-
regulated ABCA1 and MRP2 mRNA and protein levels in HepG2 cells
in a concentration-dependent manner (Figs. 2A, B and 3). Moreover,
TO901317-induced MRP2 mRNA alteration was blocked by LXRα
knockdown (Fig. 7). An endogenous LXR agonist, 25-hydroxycho-
lesterol (25-OHC), also increased ABCA1 and MRP2 mRNA and pro-
tein levels (Fig. 4). Moreover, administration of TO901317 to rats
increased Abca1 and Mrp2 mRNA and protein levels in the liver
(Fig. 5Aa, b and B). On the other hand, TO901317 had no effect on
MDR1 and BCRPmRNA levels in HepG2 cells and the rat liver (Figs. 2C,
D and 5Ac, d). These results suggest that LXR activation induced
expression of MRP2 but not that of MDR1 and BCRP. Further inves-
tigations to clarify the alteration of transport function and localization
ofMRP2 induced by LXR activation usingMRP2overexpressed cells are
in progress. Argmann et al. [38] previously reported that treatment
with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitors (statins) increased hepatic ABCA1 expression via an LXR-
dependent pathway. Therefore, endogenous and exogenous com-
pounds such as statins that affect LXR activation possibly increase
MRP2 expression and promote excretion of MRP2 substrates. More-
over, recent studies have shown that the transcription of LXRα was
induced by PPARγ, a member of the nuclear hormone receptor super-
family [39]. Three subtypes of PPAR, PPARα, PPARβ/δ and PPARγ, have
been identiﬁed. We examined the effects of treatment with each PPAR
agonist and LXRα knockdown on MRP2 expression in HepG2 cells. In
this study, increasedMRP2 expression was noted following treatment
with agonists for PPARα (cloﬁbrate), PPARβ/δ (GW0742) and PPARγ
(troglitazone) (Supplemental Fig. 1). In addition, MRP2 mRNA
alteration induced by the three PPAR agonists was blocked by LXRα
knockdown. Therefore, drugs that affect PPAR activation such as
ﬁbrates (PPARα agonists) and thiazolidinediones (PPARγ agonists)
may also increase MRP2 expression in hepatocytes.
In this study, we demonstrated that LXR activation induced
expression of MRP2 but not that of MDR1 and BCRP in hepatocytes.
Finally, endogenous and exogenous compounds that induced LXR
activation can lead to alter pharmacokinetics of MRP2 substrates.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.bbamem.2009.08.014.
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